The Green Cross Corporation

Mogam Institute for Biomedical Research

Mijung Lee

Eun Jung Song

Jongwha Won

Min-Soo Kim

Se-Ho Kim

Ki Young Chang

Sujeong Kim

Soongyu Choi

Kyuhyun Lee

Hae-Won Lee

Hyung-Kwon Lim

Dong-Sik Kim

Kwang-Won Hong

Yong-Won Shin

Yong Nam Shin

Young Seoub Park

Kyung Hwan Ryoo

Kisu Kim

Jean Man Kim

Eun-Hee Lee

Yeon Kyung Lee

Sunmi Koo

Miyoung Oh

Jung-Ae Lim

Misun Seo

Jae Hyun Park

Jae Chan Park

Ki Su Kim

Dong Hyun Seo

Ki Joon Cho

Hyemi Nam

Dong Hyuck Seo

Eunhee Lee

Kwan Yub Kang

Eui Cheol Cho

Hye-Young Park

Aerin Yoon

So-Young Eun

Hye In Yum

An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

Fusion protein comprising IDS and use thereof

The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.

Anti-CEACAM1 antibody and use thereof

The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

Anti-mesothelin antibody and composition comprising the same

The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.

Anti-glypican 3 antibody and pharmaceutical composition containing the same

Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.

Human antibodies specifically binding to the hepatitis B virus surface antigen

Growing community of inventors

Yongin-si, South Korea

Mijung Lee